Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

NCT ID: NCT05223751

Last Updated: 2025-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-07

Study Completion Date

2025-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the effect of breathing training on the 6-minute walk test in a population of heart failure patients.

Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur.

* Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breathing therapy) or the control (standard of care).
* N-terminal (NT)-pro hormone BNP (NT-proBNP): If an NT-proBNP was collected as standard of care within 3 months of enrollment, this can be used for study purposes and compared to the 6 month NT-proBNP.
* New York Heart Association Class: If the NYHA class is completed as standard of care within 3 months of enrollment, this can be used for study proposes.
* Kansas City Cardiomyopathy Questionnaire (KCCQ)
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Orientation to the Heart Rate Variability 4 (HRV4) Training application: This will include downloading, creating an account for, and training the participant on the application.

The Intervention Group will also receiving training on the Meo Health breathing therapy, which will include:

* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and custom setting the Breathe application.
* Zoom Within one month of the baseline visit, participants in the intervention group will have a one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their breathing therapy intervention.

3 Month Visit The 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group . The participant will only meet with the CRC at the 3 month visit and all assessments will be completed by the CRC.
* NYHA class
* KCCQ
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Assess compliance from HRV4 Training application questions
* Assess any possible adverse events

6 Month/Final Visit The 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group. The participant will meet with the CRC at the 6 month visit, any assessments not completed as Standard of Care (SOC), will be completed by the CRC.
* NT-proBNP: If an NT-proBNP is ordered as standard of care for the participant, this can be used for study purposes and compared to the baseline NT-proBNP.
* NYHA class: If the NYHA class is completed as standard of care, this can be used for study purposes and compared to the baseline and 3 month values.
* KCCQ
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Assess any possible adverse events

9 Month Structured Telephone Survey The 9 month structured telephone interview will take place for all participants who receive breathing training from Meo Health. Participants will be called by a study team member who will facilitate a short (3-5 minute) telephone survey about adherence and changes in health outcomes as a result of participation in the trial. (See appendix 15.4). The study team member will record all answers into REDCap. Upon completion of the survey, participants will be closed out of the study. If a study team member is unable to get in contact with a participant after two attempts, their status will be marked as "closed to follow-up" and they won't be interviewed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diastolic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HRV4 + Breathing and Humming Training

On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.

Group Type EXPERIMENTAL

Meo Health Breathing and humming exercises

Intervention Type BEHAVIORAL

The Intervention Group will receive training on the Meo Health breathing therapy, which will include:

* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.
* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.

Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.

A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.

A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.

HRV4 Only

Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meo Health Breathing and humming exercises

The Intervention Group will receive training on the Meo Health breathing therapy, which will include:

* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.
* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.

Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.

A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.

A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years or older
2. Signed informed consent
3. NYHA class II-III heart failure
4. EF ≤ 45% (echo within 1 year of enrollment)
5. At least 30 days of stable medical regimen (no new neurohormonal blockade or Sodium-glucose co-transporter 2 inhibitors (SGLT2i). Dose adjustments allowed)
6. Likely to be compliant with breath training as assessed by the provider
7. Availability of a "smart" phone and internet access
8. Established care at Lancaster General Health Penn Medicine

Exclusion Criteria

1. Cardiac resynchronization therapy (CRT) within 6 months
2. Severe Chronic obstructive pulmonary disease (COPD)
3. History of diaphragm paralysis
4. Unable or unwilling to complete respiratory training protocol
5. Decompensated or American College of Cardiology (ACC) Stage D Heart Failure (HF)
6. Prior or planned chest/abdominal or nasal/facial surgery within 6 months
7. Neuromuscular disease which impairs respiration
8. Diagnosed cognitive impairment (unable to participate in training)
9. Untreated obstructive severe sleep apnea (AHI \> 30)
10. Severe valvular heart disease
11. Uncontrolled atrial fibrillation (Ave Heart Rate (HR) \> 100 bpm)
12. Orthopedic or other limitations which impair the 6-minute walk test
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Louise von Hess Medical Research Institute

OTHER

Sponsor Role collaborator

Lancaster General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roy Small, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Director

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lancaster General Hospital

Lancaster, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-XXXX-LGHP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.